BPC-157 and TB-500: Proposed Molecular Mechanisms — NO, VEGFR2, FAK–Paxillin and ILK/Akt

RESEARCH · BPC-157 + TB-500 · MECHANISMS

BPC-157 and TB-500: Proposed Molecular Mechanisms — NO, VEGFR2, FAK–Paxillin and ILK/Akt

PurixLab’s BPC-157 + TB-500 10mg is a labelled research blend. Our earlier article, BPC-157 and TB-500: Preclinical Tendon and Cell Studies, and Why Human Data Are Almost Absent, covered tendon models and the human-data gap. This article asks a different question: which molecular pathways have actually been measured for BPC-157 and for thymosin β4 (the endogenous peptide behind the TB-500 research designation), and how solid is that mechanistic map? The blend is supplied for laboratory research use only.

BPC-157 and the nitric-oxide system

Much of the BPC-157 literature frames the peptide as interacting with nitric-oxide (NO) homeostasis rather than acting as a classic single-receptor ligand. A dedicated review summarises mutual relations with L-NAME and L-arginine across gastric mucosa, alcohol models, cardiovascular readouts and fistula healing, and notes a particular interest in eNOS-related gene effects — while acknowledging that translating NO modulation into clinical performance remains undetermined [1]. Early chick work already linked BPC-157 to NO agonist/antagonist lesion patterns: L-NAME provoked pulmonary hypertension syndrome and tissue necrosis that L-arginine or BPC-157 could blunt in that model [2]. A vascular-focused review later listed NO among several vasoactive systems (alongside VEGF and FAK) through which BPC-157 is argued to optimise vascular responses after injury [3]. These papers are mostly narrative reviews and animal pathology; they do not define a single NO-synthase binding site or a full receptor pharmacology for BPC-157.

VEGFR2, internalisation and Akt–eNOS

A clearer cell-signalling paper comes from endothelial models. Hsieh and colleagues reported that BPC-157 increased vessel density in chick chorioallantoic membrane and tube-formation assays, accelerated blood-flow recovery in rat hind-limb ischaemia, and raised vascular VEGFR2 expression in ischaemic muscle. In human vascular endothelial cells, BPC-157 increased VEGFR2 mRNA and protein (but not VEGF-A), promoted VEGFR2 internalisation that dynasore blocked, and time-dependently activated a VEGFR2–Akt–eNOS pathway that dynasore also suppressed [4]. Separately, in an alkali-burn skin model, topical BPC-157 accelerated wound closure with better granulation and collagen deposition by day 18, raised VEGF expression in wounded skin, and, in HUVECs, promoted proliferation, migration, tube formation and ERK1/2-linked transcriptional readouts including c-Fos, c-Jun and Egr-1 [5]. Together these studies support angiomodulatory signalling in rodents and cultured endothelium; they are not human efficacy trials, and the blend format used commercially is not what those assays tested.

FAK–paxillin and growth-hormone receptor in tendon fibroblasts

In rat Achilles tendon fibroblasts, BPC-157 accelerated explant outgrowth, improved survival under hydrogen-peroxide stress, and increased migration and spreading. Proliferation by MTT was not directly increased, but F-actin formation rose, and phosphorylation of FAK and paxillin increased while total FAK/paxillin protein stayed unaltered — pointing to a FAK–paxillin pathway for migration rather than simple mitogenesis [6]. A follow-up microarray study in the same cell type flagged growth hormone receptor as among the most up-regulated transcripts; BPC-157 raised GHR at mRNA and protein levels, and adding growth hormone then increased proliferation (MTT and PCNA) and activated Janus kinase 2 in BPC-157-pretreated fibroblasts [7]. That is a coherent fibroblast story: cytoskeletal signalling plus sensitisation to an endocrine ligand. It remains an in vitro/ex vivo tendon-fibroblast programme, not a mapped pharmacokinetics or receptor-occupancy study for a finished product.

Thymosin β4: ILK/Akt beyond actin sequestration

TB-500 is a research designation tied to thymosin β4 sequences; the peer-reviewed signalling map is written for thymosin β4 itself. Beyond G-actin sequestration, Bock-Marquette and colleagues showed that thymosin β4 forms a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt. In embryonic and postnatal cardiomyocytes it promoted migration and survival, and after coronary ligation in mice it up-regulated ILK and Akt activity, enhanced early myocyte survival and improved cardiac function [8]. In endothelial progenitor cells under serum deprivation, thymosin β4 reduced apoptosis in a manner abolished by PI3K inhibitors or ILK-siRNA, increased the Bcl-2/Bax ratio, and immunoprecipitated with ILK while raising ILK activity [9]. A colorectal-cancer cell study likewise placed thymosin β4 upstream of ILK/AKT/β-catenin invasion programmes — useful as pathway corroboration, but in a tumour context that also underlines why uncontrolled angiogenic or migratory signalling needs cautious interpretation [10].

How strong is the mechanistic evidence?

  • Stronger. VEGFR2 internalisation/Akt–eNOS in endothelium [4]; FAK–paxillin phosphorylation and GHR up-regulation in tendon fibroblasts [6,7]; PINCH–ILK–Akt complex biochemistry for thymosin β4 [8,9].
  • Weaker or broader. System-level NO narratives spanning many organs [1,3]; early L-NAME chick pathology [2]; cancer-cell ILK cascades that are mechanistically informative but indication-distant [10].
  • Missing. Controlled human mechanism studies for BPC-157; blend-specific ADME; head-to-head receptor occupancy for TB-500 versus native thymosin β4 in the same assays.

BPC-157 + TB-500 10mg at PurixLab

BPC-157 + TB-500 10mg: a labelled lyophilized research vial combining BPC-157 and TB-500 (10mg labelled content per vial), C$89 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View BPC-157 + TB-500 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-35. PubMed 23755725 · doi:10.2174/13816128113190990411
  2. Grabarevic Z, Tisljar M, Artukovic B, et al. The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. J Physiol Paris. 1997;91(3-5):139-49. PubMed 9403788 · doi:10.1016/s0928-4257(97)89478-8
  3. Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-5. PubMed 23782145 · doi:10.2174/13816128113199990421
  4. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PubMed 27847966 · doi:10.1007/s00109-016-1488-y
  5. Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-99. PubMed 25995620 · PMC4425239 · doi:10.2147/DDDT.S82030
  6. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. PubMed 21030672 · doi:10.1152/japplphysiol.00945.2010
  7. Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. PubMed 25415472 · PMC6271067 · doi:10.3390/molecules191119066
  8. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-72. PubMed 15565145 · doi:10.1038/nature03000
  9. Zhao Y, Qiu F, Xu S, et al. Thymosin β4 activates integrin-linked kinase and decreases endothelial progenitor cells apoptosis under serum deprivation. J Cell Physiol. 2011;226(11):2798-806. PubMed 21935929 · doi:10.1002/jcp.22624
  10. Piao Z, Hong CS, Jung MR, et al. Thymosin β4 induces invasion and migration of human colorectal cancer cells through the ILK/AKT/β-catenin signaling pathway. Biochem Biophys Res Commun. 2014;452(3):858-64. PubMed 25218472 · doi:10.1016/j.bbrc.2014.09.012

Leave a Comment

Your email address will not be published. Required fields are marked *